EXHIBIT 99.1


Contact:

Investors:                                                Media:
Ann Tanabe                                                Brad Miles
Encysive Pharmaceuticals                                  BMC Communications
(713) 796-8822                                            (212) 477-9007 ext. 17

Hershel Berry
The Trout Group
(415) 392-3385

FOR IMMEDIATE RELEASE

   ENCYSIVE PHARMACEUTICALS REITERATES GUIDANCE FOR STRIDE-2 TRIAL ENROLLMENT


HOUSTON, TX - JULY 6, 2004 - Encysive Pharmaceuticals (NASDAQ: ENCY) today
confirmed that enrollment in the STRIDE-2 clinical trial is expected to complete
in the third quarter of 2004. Enrollment is close to three quarters complete in
this 240 patient study. The Company expects to provide its next update when
STRIDE-2 has been fully enrolled.

STRIDE-2 is a Phase III, randomized, double-blind, placebo-controlled safety and
efficacy study of Thelin(TM) treatment with an open-label bosentan arm in
patients with pulmonary arterial hypertension (PAH). Patients are randomized to
receive one of four treatments: Thelin 50 mg once daily, Thelin 100 mg once
daily, placebo once daily, or bosentan twice daily according to the package
insert. The duration of the trial is 18 weeks.

ABOUT THELIN(TM) AND PAH

Thelin is a small molecule that blocks the action of endothelin, a potent
mediator of blood vessel constriction and growth of smooth muscle in vascular
walls. Endothelin receptor antagonists may prove to be effective in the
treatment of a variety of diseases where the regulation of vascular constriction
is important. Thelin is 6,500 fold selective in the targeting of the endothelin
A receptor.

Pulmonary arterial hypertension (PAH) is a condition that involves high blood
pressure and structural changes in the walls of the pulmonary arteries, which
are the blood vessels that connect the right side of the heart to the lungs. PAH
causes shortness of breath, limits activity, and is eventually fatal unless
treated successfully with heart and lung transplant. Primary and secondary PAH
are estimated to afflict approximately 80,000 to 100,000 people worldwide, many
of whom are children and young women.

Side effects of Thelin(TM) seen in the program to date, and which occurred more
frequently than in placebo, include liver dysfunction (increased ALT and AST),
headache, edema,


                                                                               1

                                                                    EXHIBIT 99.1


constipation, nasal congestion and flushing. Because Thelin inhibits the
metabolism of warfarin, the dose of warfarin should be adjusted downward when
co-administered with Thelin.

ABOUT ENCYSIVE PHARMACEUTICALS

Encysive Pharmaceuticals Inc., a biopharmaceutical company focused on the
discovery, development and commercialization of novel drugs, is recognized for
our expertise in small molecule drug development and vascular biology.
Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline
for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III
development of the endothelin antagonist, Thelin, for pulmonary arterial
hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in
Phase II development with the selectin antagonist bimosiamose in asthma,
psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other
research and development programs ongoing for a range of cardiovascular and
inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit
our web site: www.encysive.com.

This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
are subject to certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Among those risks, trends and
uncertainties are timing and cost of our clinical trials, attainment of research
and clinical goals and milestones of product candidates, attainment of required
government approvals, sales levels of our products and availability of financing
and revenues sufficient to fund development of product candidates and
operations. In particular, careful consideration should be given to cautionary
statements made in the various reports Encysive Pharmaceuticals, including as
Texas Biotechnology Corporation, has filed with the Securities and Exchange
Commission. The Company undertakes no duty to update or revise these
forward-looking statements.

                                      # # #


                                                                               2